RESPONSIVENESS TO RECOMBINANT HUMAN ERYTHROPOIETIN OR ERYTHROID PROGENITORS

对重组人类红细胞生成素或红细胞祖细胞的反应

• 批准号: 6279792
• 负责人: ROBIN OHLS
• 金额: $ 2.62万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279792
• 关键词: clinical research; erythropoiesis; erythropoietin; human subject; low birth weight infant human; recombinant proteins; tissue /cell culture

The effectiveness of exogenously administered recombinant human erythropoietin (Epo) has not been closely studied in many infants <1000 grams, the population most at risk for repeated blood transfusions. To determine if their erythroid progenitors are responsive to Epo, light density cells from cord blood of preterm infants <1000 grams will be cultured in various concentrations of Epo. Term cord blood will be used for comparison.

外源性施用重组人的有效性 促红细胞生成素（Epo）尚未在许多<1000岁的婴儿中进行过深入研究 克，重复输血的风险最高的人群。 到 确定他们的红系祖细胞是否对Epo，光 来自<1000克的早产儿的脐带血的密度细胞将被 在不同浓度的Epo中培养。将使用足月脐带血 以供比较。